sankyo co ltd annual report 2004 c2 mevalotin pravastatin as a revolutionary new drug from japan and godsend to hyperlipidemia patients olmesartan strategic global product in light of the high regard that it received best class candidate early development stage ourselves s framework for providing comprehensive support people with lifestyle related diseases has been highly praised by many health care professionals arteriosclerosis cs 505 747 livalo hypertension olmetec calblock acecol captoril diabetes fastic 917 011 872 under a1 comprise approximately 65 ethical pharmaceutical sales on non consolidated basis lineup disease medications includes hmg coa reductase inhibitor treating arb ace inhibitors calcium channel block er fast acting agent lowers blood sugar levels after meals addition most drugs currently pipeline are have combination
